Get the Stockscreener App
4.57
11.09%
-0.57
After Hours:
4.63
0.06
+1.31%
Adicet Bio Inc stock is traded at $4.57, with a volume of 188.44K.
It is down -11.09% in the last 24 hours and down -49.50% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
See More
Previous Close:
$5.14
Open:
$5.14
24h Volume:
188.44K
Relative Volume:
0.80
Market Cap:
$42.78M
Revenue:
$24.99M
Net Income/Loss:
$-108.83M
P/E Ratio:
-0.3041
EPS:
-15.0286
Net Cash Flow:
$-91.62M
1W Performance:
-18.54%
1M Performance:
-49.50%
6M Performance:
-43.23%
1Y Performance:
-72.54%
1-Day Range:
$4.57
$5.14
1-Week Range:
$4.57
$5.84
52-Week Range:
$4.57
$17.04
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
4.57 | 42.78M | 24.99M | -108.83M | -91.62M | -15.03 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-26 | Resumed | Jefferies | Buy |
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
A new hire waits a year to gain the right to buy Adicet shares - Stock Titan
Every patient in Adicet's lupus study stopped immune-suppressing drugs - Stock Titan
Adicet Bio (Nasdaq:ACET)Stock Analysis - Simply Wall Street
Adicet Bio (NasdaqCM:ACET) Stock Forecast & Analyst Predictions - Simply Wall Street
At $10.99 a share, Gossamer Bio (GOSS) director Sandra Milligan receives a stock option. - Stock Titan
Gossamer Bio grants director options on 10,000 shares - Stock Titan
Devpratim Chakraborty, Brigit SVP, reported no direct Upbound Group (UPBD) shares as of September 22. - Stock Titan
[Form 3] Electra Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Red Robin Gourmet Burgers, Inc.Common Stock (NQ: RRGB - The Chronicle-Journal
Adicet Bio, Inc. (NASDAQ:ACET) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adicet Bio (NASDAQ:ACET) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - marketbeat.com
Stock option sale planned at ScanSource (NASDAQ: SCSC) for 2026 - Stock Titan
Adicet Bio Highlights Prula-cel Autoimmune CAR-T Pipeline Progress - TipRanks
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView
Adicet Bio Stock Price Forecast. Should You Buy ACET? - StockInvest.us
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? - Yahoo Finance
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Upgraded to Strong-Buy at Jefferies Financial Group - marketbeat.com
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
A biotech CEO will speak in New York Sept. 15. Audio will be online. - Stock Titan
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC and Prepares Prula-Cel Data Release - Kalkine Media
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC, Prula-cel Data Expected in September 2026 - Kalkine Media
Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Drop in Short Interest - MarketBeat
Adicet Bio advances CAR-T programs and clinical pipeline - grafa.com
Adicet Bio completes prula-cel Phase 1 SLE analysis - TipRanks
Adicet Bio says prula-cel last patient visit complete; topline data due Sept 2026, ADI-212 IND cleared - TradingView
The final patient visit is complete in a lupus cell-therapy study. Adicet Bio expects results from 22 patients in September. - stocktitan.net
Adicet Bio grants a new hire options on 1,500 shares over four years - Stock Titan
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street Zen - marketbeat.com
Press Release Service: Adicet Bio Announces FDA Clearance of IND Application for ADI-212 - CRISPR Medicine News
Adicet Bio Gets FDA Clearance for IND for ADI-212 in prostate cancer - marketscreener.com
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com Canada
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com India
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com UK
Adicet Bio receives FDA clearance for prostate cancer trial - investing.com
FDA clears Adicet Bio's application to study a gene-edited prostate cancer therapy - Stock Titan
Here's Why You Should Add ACET Stock to Your Portfolio Now - Yahoo Finance
Adicet (ACET) Trading: Adds 0.32% to Close at $9.41 in the Current Update; Key Range - vinanet.vn
ETFs Investing in Adicet Bio Inc Stocks - TradingView
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Eastern Progress
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
ACET Q2 2026 Earnings: Narrower-Than-Expected Loss of $1.99 Per Share Buoys SharesSegment Revenue Breakdown - vinanet.vn
RA Capital discloses 9.99% Adicet Bio (ACET) stake with warrant blocker - Stock Titan
Adicet Bio (ACET) - Zacks Investment Research
Adicet Bio: A Cheap Gamma Delta T-Cell Play (NASDAQ:ACET) - Seeking Alpha
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Zacks Investment Research
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Yahoo Finance
Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsETF Flow - Vinanet
Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsVanna Flow - dars.gov.et
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
Adicet Bio Inc Stock (ACET) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| OrbiMed Genesis Master Fund, L | Shareholder |
Apr 09 '26 |
Proposed Sale |
6.55 |
78,499 |
514,168 |
0 |
| OrbiMed Israel Partners II, L. | Shareholder |
Apr 08 '26 |
Proposed Sale |
6.55 |
40,416 |
264,725 |
0 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 08 '26 |
Sale |
6.42 |
72,939 |
468,082 |
0 |
| OrbiMed Israel Partners Limite | Shareholder |
Apr 07 '26 |
Proposed Sale |
6.43 |
64,242 |
413,076 |
0 |
| ORBIMED ADVISORS LLC | 10% Owner |
Apr 07 '26 |
Sale |
6.52 |
31,719 |
206,765 |
32,523 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 19 '26 |
Buy |
7.21 |
74,268 |
535,472 |
1,107,873 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Feb 18 '26 |
Buy |
7.04 |
74,577 |
525,022 |
1,033,605 |
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 08 '25 |
Buy |
1.00 |
5,000,000 |
5,000,000 |
9,026,359 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):